Bring Your Pregnancy History to Your Cardiologist

This pillar has shown, article by article, that a woman’s reproductive history is cardiovascular information. This final article turns that into a single action. The history only protects a woman if it reaches the person assessing her heart, and the system reliably fails to collect it. So the move is specific, simple, and almost absurdly high-value: write it down, and bring it.

The Mechanism

The gap between what a woman knows about her own reproductive history and what appears in her cardiovascular record is not usually the result of clinical judgment. It is a structural failure of intake forms. Standard cardiovascular intake questionnaires were largely designed around male risk profiles and have been updated only partially. They ask about smoking, hypertension, diabetes, and family history. They rarely ask whether a woman had preeclampsia, delivered preterm, developed gestational diabetes, or reached menopause before forty-five. Those questions are absent from most general cardiology intake documents, and busy clinical visits do not fill that gap reliably.

The consequence is real. Preeclampsia doubles the long-term risk of cardiovascular disease and raises stroke risk approximately 1.8-fold, according to pooled data reviewed by Bellamy et al. in the Lancet (2007). Gestational diabetes is associated with roughly a sevenfold increase in the risk of developing type 2 diabetes, a major cardiovascular risk driver, and with elevated cardiovascular risk independent of subsequent diabetes (Bellamy et al., Lancet, 2009). Preterm birth before 37 weeks is associated with approximately a 38% higher risk of cardiovascular disease in the mother, per Tanz et al. in JAMA Cardiology (2021). Delivering a small-for-gestational-age baby carries similar elevations. Early menopause, defined as occurring before forty-five, is associated with a 50% increase in the risk of cardiovascular disease, per the British Heart Foundation-funded analysis by Gong et al. published in the European Heart Journal (2022).

None of these are rare. Preeclampsia affects approximately 5 to 8 percent of pregnancies in the United States; gestational diabetes affects roughly 6 to 9 percent; preterm birth affects about 10 percent. Taken together, a substantial fraction of women carry at least one of these risk-relevant histories. And because intake forms do not ask, that history lands nowhere unless a woman brings it herself.

The mechanism by which pregnancy complications elevate long-term risk is not simply that sick women have sick pregnancies. Evidence increasingly supports the hypothesis that complications like preeclampsia reveal underlying endothelial dysfunction and vascular susceptibility that precede the pregnancy and persist afterward. The pregnancy acts as a stress test on the vascular system, and the complication is the result of a system that was already operating under strain. That underlying susceptibility is what drives the long-term risk, which is why the elevated danger persists for years to decades after a single affected pregnancy. A woman is not punished twice; she is being told twice, first by the pregnancy and then by her risk profile, that her vascular system warrants attention.

Understanding why the intake system fails helps clarify why the burden falls on the woman. The Pooled Cohort Equations, which are the standard risk calculation tool used in the United States since the 2013 ACC/AHA guidelines, incorporate age, sex, race, total cholesterol, HDL cholesterol, systolic blood pressure, treatment status, diabetes, and smoking. The equations do not include reproductive history. When a clinician enters those values and gets a 10-year risk estimate, that estimate is blind to a woman’s preeclampsia, her gestational diabetes, and her age at menopause. The math literally cannot account for what the form never asked.

What the Evidence Shows

The American Heart Association incorporated adverse pregnancy outcomes into its 2018 Guideline on the Management of Blood Cholesterol, listing preeclampsia, gestational hypertension, preterm delivery, and small-for-gestational-age birth as risk-enhancing factors that inform the statin decision in borderline-risk women. The 2019 ACC/AHA Primary Prevention Guideline extended this, recommending that clinicians consider the history of adverse pregnancy outcomes as part of the overall risk assessment in women. These are not fringe positions: they represent the mainstream of guidelines-level cardiovascular medicine.

Despite this guideline recognition, the practice gap has been documented. A study by Brown et al. published in Circulation: Cardiovascular Quality and Outcomes (2020) found that most women with a history of preeclampsia were not receiving cardiovascular risk screening recommended by current guidelines. When Parikh et al. surveyed cardiologists and internists (Hypertension, 2021), they found that fewer than half routinely asked about pregnancy complications during cardiovascular evaluations. The form does not ask, the clinician does not ask in the rush of a visit, and the history is lost.

The 2022 American Heart Association Statement on Cardiovascular Risk in Women, authored by Vogel et al. and published in Circulation, listed reproductive history, including not only pregnancy complications but also early menopause, menstrual irregularity, polycystic ovary syndrome, and autoimmune disease, as critical components of a complete women’s cardiovascular risk assessment. That statement was explicit: clinicians should ask, and women should volunteer if not asked.

Migraine with aura warrants a specific mention. Women who experience migraine with aura have approximately a twofold elevated risk of ischemic stroke compared with women without migraine (Kurth et al., Neurology, 2012). The mechanism is thought to involve cortical spreading depression, vascular reactivity, and prothrombotic changes during migraine attacks. This is a sex-specific risk modifier that most general cardiovascular intake forms do not capture, and its inclusion changes the stroke-risk component of the overall cardiovascular picture materially.

Autoimmune diseases, including rheumatoid arthritis, systemic lupus erythematosus, and psoriasis, are far more prevalent in women than men and carry independent cardiovascular risk. Rheumatoid arthritis, for example, carries roughly a 50% increase in cardiovascular risk compared to the general population (Peters et al., Annals of the Rheumatic Diseases, 2010), operating through inflammatory pathways that accelerate atherosclerosis. Lupus carries an even larger relative risk, particularly in younger women, with some studies showing a 50-fold increase in myocardial infarction risk in women with lupus aged 35 to 44 (Manzi et al., American Journal of Epidemiology, 1997). These are not secondary considerations; they are primary risk factors for which most cardiovascular intake forms allocate no dedicated space.

Polycystic ovary syndrome (PCOS) is a further example. PCOS affects an estimated 6 to 12 percent of women of reproductive age in the United States, according to the CDC. It is associated with insulin resistance, dyslipidemia, hypertension, and an adverse metabolic profile that collectively elevate cardiovascular risk. A meta-analysis by de Groot et al. (Human Reproduction Update, 2011) found that women with PCOS had significantly elevated rates of subclinical atherosclerosis. PCOS does not appear on standard cardiovascular intake forms as a specific question, so it is another data point that disappears unless the woman supplies it.

Early Menopause and Surgical Menopause: The Understated Signals

Among the items that belong on a woman’s reproductive history page, the age at menopause is among the least consistently documented in cardiovascular risk assessments despite its independent contribution to risk.

Early natural menopause, defined as final menstrual period before age 45, is associated with substantially elevated cardiovascular risk compared to menopause at the median age of 51 to 52. The Gong et al. analysis published in the European Heart Journal in 2022, drawing on UK Biobank data covering more than 144,000 women, found that women who reached natural menopause before 45 had a 50 percent higher risk of cardiovascular disease compared with women who reached it at 50 to 51, after adjusting for traditional risk factors. The earlier the menopause, the higher the risk gradient, consistent with the interpretation that cumulative years of estrogen exposure matters to vascular health.

Surgical menopause, which results from bilateral oophorectomy and removes ovarian estrogen production abruptly rather than through a gradual decline, carries additional cardiovascular risk on top of early natural menopause. Rocca and colleagues at the Mayo Clinic, analyzing the Rochester Epidemiology Project cohort with long-term follow-up, found that bilateral oophorectomy before age 45 was associated with significantly elevated cardiovascular mortality in subsequent decades, with a hazard ratio of approximately 1.84 for ischemic heart disease events compared to women whose ovaries were preserved to natural menopause. The abruptness of estrogen withdrawal matters: the cardiovascular system has no time to adapt to the loss of estrogen’s vasodilatory, anti-inflammatory, and LDL receptor-upregulating effects, unlike the gradual transition of natural menopause. 3 / Early

For women who underwent bilateral oophorectomy before natural menopause age, hormone therapy initiated promptly and continued at least until the age of natural menopause represents the most evidence-supported cardiovascular risk mitigation strategy. This is distinct from the more nuanced discussion of hormone therapy at the age of natural menopause; in premenopausal oophorectomy, the evidence is stronger because it is replacing what was removed rather than adding what has already naturally declined.

On the written history: include the age at menopause (natural or surgical), the reason if surgical, and whether hormone therapy was used and for how long. This context changes how the cardiovascular signal from early menopause is weighted and whether hormone therapy history modifies the overall risk picture.

Why the Timing Matters

There is a specific window when this information is most consequential, and that window is not always obvious. A woman in her late thirties or early forties, years past a complicated pregnancy and years before what most risk algorithms would flag as elevated cardiovascular risk, is precisely the woman whose history is most likely to change the clinical calculus. The risk-enhancing effect of preeclampsia and gestational diabetes begins operating on the vascular system immediately after the pregnancy and continues for decades.

Women with a history of preeclampsia should ideally have an annual blood pressure check, earlier and more regular lipid monitoring than is standard for low-risk women, and a formal cardiovascular risk assessment beginning no later than their early forties, per the AHA 2022 statement. If a woman with that history is in her forties and has not yet had a risk conversation that accounts for the preeclampsia, she is behind where the guidelines would put her, and the primary reason is almost certainly that no one thought to ask.

The visit where the history is first presented does not have to be the only payoff. A woman who brings her reproductive history to a general internist, an obstetrician-gynecologist, or any other clinician who maintains a longitudinal record creates a trail that should follow her into cardiology. The best use of the history is to ensure it is documented in the problem list or medical history section of her electronic health record in a way that makes it retrievable and visible to any future clinician.

What to Do This Week

1. Write your complete reproductive and sex-specific history on one page, including: any hypertensive disorder of pregnancy (including preeclampsia or gestational hypertension), gestational diabetes, preterm birth (before 37 weeks), delivery of a small-for-gestational-age baby, the age menopause occurred, any autoimmune disease including lupus, rheumatoid arthritis, or psoriasis, migraine with aura, PCOS, and family history of heart disease in a first-degree relative before age sixty-five in women or age fifty-five in men.

2. Include events from any pregnancy, even those from years or decades ago. The risk association persists over time. Label each item with its approximate date so the clinician can see the timeline and the years of elapsed risk.

3. At your next appointment, hand the page over at the start of the visit. Do not wait for the clinician to ask; the intake form will not prompt it and the visit schedule does not allow for it to emerge naturally.

4. Ask specifically: does this history change my cardiovascular risk category, and does it change my recommended monitoring or the timing of prevention? The goal is to confirm that the information has been incorporated into a plan, not merely recorded in a note.

5. If your history includes preeclampsia or gestational hypertension, ask whether your blood pressure monitoring plan accounts for elevated long-term risk; home monitoring and lower treatment thresholds may be appropriate earlier than guidelines for the general population would suggest.

A woman’s reproductive history is cardiovascular information that the system rarely collects, which means she has to bring it. Writing it on one page and placing it in front of her clinician is the simplest, highest-value action in this entire wing, and it is the one move that makes everything else in the reproductive-clock pillar actually count.